Roberts Glore & CO Inc Biogen Inc. Transaction History

Roberts Glore & CO Inc

  • $333 Million
  • Q2 2025

A detailed history of Roberts Glore & CO Inc transactions in Biogen Inc. stock. As of the latest transaction made, Roberts Glore & CO Inc holds 4,344 shares of BIIB stock, worth $635,179. This represents 0.16% of its overall portfolio holdings.

Number of Shares
4,344
Previous 4,163 4.35%
Holding current value
$635,179
Previous $569,000 4.22%
% of portfolio
0.16%
Previous 0.18%

Shares

32 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 07, 2025
BUY
$113.38 - $135.49 $20,521 - $24,523
181 Added 4.35%
4,344 $545,000
Q1 2025

May 09, 2025
BUY
$133.43 - $153.27 $83,660 - $96,100
627 Added 17.73%
4,163 $569,000
Q4 2024

Feb 07, 2025
SELL
$146.47 - $191.55 $21,677 - $28,349
-148 Reduced 4.02%
3,536 $540,000
Q3 2024

Nov 14, 2024
BUY
$189.07 - $236.8 $45,376 - $56,832
240 Added 6.97%
3,684 $714,000
Q2 2024

Aug 14, 2024
BUY
$190.52 - $236.72 $16,956 - $21,068
89 Added 2.65%
3,444 $798,000
Q1 2024

May 09, 2024
BUY
$212.02 - $267.71 $1,908 - $2,409
9 Added 0.27%
3,355 $723,000
Q4 2023

Feb 12, 2024
BUY
$222.59 - $267.94 $890 - $1,071
4 Added 0.12%
3,346 $865,000
Q3 2023

Nov 13, 2023
SELL
$253.3 - $285.89 $69,657 - $78,619
-275 Reduced 7.6%
3,342 $858,000
Q2 2023

Aug 14, 2023
SELL
$275.25 - $318.06 $59,729 - $69,019
-217 Reduced 5.66%
3,617 $1.03 Million
Q1 2023

May 08, 2023
SELL
$256.56 - $292.34 $22,833 - $26,018
-89 Reduced 2.27%
3,834 $1.07 Million
Q4 2022

Feb 13, 2023
SELL
$252.44 - $306.72 $429,905 - $522,344
-1,703 Reduced 30.27%
3,923 $1.09 Million
Q3 2022

Nov 07, 2022
SELL
$194.69 - $268.46 $104,159 - $143,626
-535 Reduced 8.68%
5,626 $1.5 Million
Q2 2022

Aug 11, 2022
BUY
$187.54 - $223.02 $152,470 - $181,315
813 Added 15.2%
6,161 $1.26 Million
Q1 2022

May 02, 2022
BUY
$193.77 - $244.14 $42,435 - $53,466
219 Added 4.27%
5,348 $1.13 Million
Q4 2021

Feb 11, 2022
SELL
$223.92 - $287.77 $199,288 - $256,115
-890 Reduced 14.79%
5,129 $1.23 Million
Q3 2021

Nov 12, 2021
SELL
$282.99 - $369.05 $5,659 - $7,381
-20 Reduced 0.33%
6,019 $1.7 Million
Q2 2021

Aug 10, 2021
BUY
$259.0 - $414.71 $27,972 - $44,788
108 Added 1.82%
6,039 $2.09 Million
Q1 2021

May 06, 2021
BUY
$242.95 - $284.63 $34,498 - $40,417
142 Added 2.45%
5,931 $1.66 Million
Q4 2020

Feb 09, 2021
BUY
$236.26 - $355.63 $58,592 - $88,196
248 Added 4.48%
5,789 $1.42 Million
Q3 2020

Nov 06, 2020
BUY
$264.77 - $305.71 $27,536 - $31,793
104 Added 1.91%
5,541 $1.57 Million
Q2 2020

Aug 13, 2020
SELL
$258.66 - $342.55 $6,207 - $8,221
-24 Reduced 0.44%
5,437 $1.45 Million
Q1 2020

May 11, 2020
BUY
$268.85 - $341.04 $12,367 - $15,687
46 Added 0.85%
5,461 $1.73 Million
Q4 2019

Feb 13, 2020
BUY
$220.06 - $304.07 $542,227 - $749,228
2,464 Added 83.5%
5,415 $1.61 Million
Q3 2019

Nov 08, 2019
BUY
$217.44 - $243.88 $59,143 - $66,335
272 Added 10.15%
2,951 $687,000
Q2 2019

Aug 09, 2019
BUY
$219.29 - $241.72 $39,472 - $43,509
180 Added 7.2%
2,679 $627,000
Q1 2019

May 14, 2019
SELL
$216.71 - $338.96 $19,503 - $30,506
-90 Reduced 3.48%
2,499 $591,000
Q4 2018

Feb 08, 2019
BUY
$278.5 - $352.75 $1,949 - $2,469
7 Added 0.27%
2,589 $779,000
Q2 2018

Aug 10, 2018
BUY
$257.52 - $306.91 $27,039 - $32,225
105 Added 4.24%
2,582 $749,000
Q1 2018

May 08, 2018
BUY
$260.13 - $367.91 $23,151 - $32,743
89 Added 3.73%
2,477 $678,000
Q4 2017

Feb 09, 2018
SELL
$307.64 - $344.58 $33,840 - $37,903
-110 Reduced 4.4%
2,388 $761,000
Q3 2017

Nov 08, 2017
BUY
$281.15 - $329.69 $16,869 - $19,781
60 Added 2.46%
2,498 $782,000
Q2 2017

Aug 15, 2017
BUY
N/A
2,438
2,438 $662,000

Others Institutions Holding BIIB

# of Institutions
1,030
Shares Held
131M
Call Options Held
2.84M
Put Options Held
2.54M
View Full List

About BIOGEN INC.

BIIB Quotes by TradingView
  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $21.1B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Roberts Glore & CO Inc Portfolio

Follow Roberts Glore & CO Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Roberts Glore & CO Inc , based on Form 13F filings with the SEC.

News

Stay updated on Roberts Glore & CO Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email